The Journal of Urology
Volume 175, Issue 4 , Pages 1353-1358 , April 2006

Efficacy and Safety of Histrelin Subdermal Implant in Patients With Advanced Prostate Cancer

  • Peter N. Schlegel

      Affiliations

    • Financial interest and/or other relationship with Valera Pharmaceuticals.
    • Corresponding Author InformationCorrespondence: Starr 900, Department of Urology, New York Presbyterian Hospital-Weill Cornell Medical Center, 525 East 68th St., New York, New York 10021 (telephone: 212-746-5491; FAX: 212-746-8425)
    • ,
  • Histrelin Study Group

Received 15 December 2004

References 

  1. Jemal A , Tiwari RC , Murray T , Ghafoor A , Samuels A , Ward E , et al.   Cancer statistics, 2004 . CA Cancer J. Clin . 2004;54:8
  2. Oh WK , Kantoff PW . Management of hormone refractory prostate cancer current standards and future prospects . J Urol . 1998;160:1220
  3. Huggins C , Stevens RE , Hodges CV . Studies on prostate cancer. II (The effects of castration on advanced carcinoma of the prostate gland) . Arch Surg . 1941;43:209
  4. Huggins C , Hodges CV . Studies on prostatic cancer I. The effect of castration, of estrogen and of androgen injection on serum phoshatases in metastatic carcinoma of the prostate . Cancer Res . 1941;1:293
  5. Clayton RN , Catt KJ . Gonadotropin-releasing hormone receptors characterization, physiological regulation, and relationship to reproductive function . Endocr Rev . 1981;2:186
  6. Schally AV , Kastin AJ , Coy DH , Edward T . Tyler Prize Oration: LH-releasing hormone and its analogues: recent basic and clinical investigations . Int J Fertil . 1976;21:1
  7. Walsh PC . Physiologic basis for hormonal therapy in carcinoma of the prostate . Urol Clin North Am . 1975;2:125
  8. The Leuprolide Study Group . Leuprolide versus diethylstilbestrol for metastatic prostate cancer . N Engl J Med . 1984;311:1281
  9. Sartor O . Eligard leuprolide acetate in a novel sustained-release delivery system . Urology . 2003;61(suppl):25
  10. Ascoli M , Segaloff DL . Adenohypophyseal hormones and their hypothalamic releasing factors . In:  Goodman LS ,  Limbird LE ,  Milinoff PB ,  Ruddon RW ,  Gilman AG editor. Goodman and Gilman’s (The Pharmacological Basis of Therapeutics) . 9th ed.. New York: McGraw-Hill; 1996;p. 1377; sect. XIII, chapt. 55
  11. Schlegel PN , Kuzma P , Frick J , Farkas A , Gomahr A , Spitz I , et al.   Effective long-term androgen suppression in men with prostate cancer using a hydrogel implant with the GnRH agonist histrelin . Urology . 2001;58:578
  12. Chertin B , Spitz IM , Lindenberg T , Algur N , Zer T , Kuzma P , et al.   An implant releasing the gonadotropin hormone-releasing hormone agonist histrelin maintains medical castration for up to 30 months in metastatic prostate cancer . J Urol . 2000;163:838

 Supported by a grant from Valera Pharmaceuticals.

PII: S0022-5347(05)00649-X

doi: 10.1016/S0022-5347(05)00649-X

The Journal of Urology
Volume 175, Issue 4 , Pages 1353-1358 , April 2006

Article Tools

* Image Usage & Resolution